Immune System News and Research

RSS

SCYNEXIS announces results from SCY-635 Phase 2a study on HCV

SCYNEXIS, Inc. today announced that the results of a Phase 2a study of lead candidate SCY-635 for the treatment of the hepatitis C virus (HCV) will be the subject of an oral presentation at the 63rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), taking place from November 9-13 in Boston, Massachusetts.

7 Nov 2012

Researchers show how bacteria control processes in human cells

Bacteria can talk to each other via molecules they themselves produce. The phenomenon is called quorum sensing, and is important when an infection propagates. Now, researchers at Link-ping University in Sweden are showing how bacteria control processes in human cells the same way.

6 Nov 2012

Pfizer receives FDA approval for Xeljanz to treat rheumatoid arthritis

The U.S. Food and Drug Administration today approved Xeljanz (tofacitinib) to treat adults with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response to, or who are intolerant of, methotrexate.

6 Nov 2012

Sabin initiates Part II of Na-GST-1 vaccine Phase I hookworm trial

The Sabin Vaccine Institute (Sabin) today announced the start of Part II of its Phase I clinical trial of the Na-GST-1 vaccine candidate, marking another major milestone in the progress toward developing a human hookworm vaccine.

6 Nov 2012

Bristol-Myers Squibb welcomes decision by NICE to recommend Yervoy for advanced melanoma

Today, Bristol-Myers Squibb is pleased to welcome the decision by The National Institute for Health and Clinical Excellence (NICE) to recommend Yervoy (ipilimumab) for the treatment of previously-treated advanced (unresectable or metastatic) melanoma within the Final Appraisal Determination (FAD).

3 Nov 2012

NICE decides to recommend Bristol-Myers Squibb’s YERVOY for treatment of advanced melanoma

Bristol-Myers Squibb Company is pleased to announce that today the National Institute of Health and Clinical Excellence (NICE) has decided to recommend YERVOY (ipilimumab), which is approved in the European Union for the treatment of previously-treated metastatic (advanced) melanoma, within the Final Appraisal Determination (FAD).

3 Nov 2012

Baylor University receives two new federal grants for research on Gulf War illness

Baylor University has been awarded two new federal grants for research on Gulf War illness, the complex medical condition that affects veterans of the 1991 war. The grants, from the Office of Congressionally Directed Medical Research Programs of the U.S. Department of Defense, total nearly $1.6 million, and bring current federal funding for Baylor's Gulf War research program to over $2.3 million.

3 Nov 2012

AeriSeal System appears to be effective in treating emphysema

Researchers at the University of Alabama at Birmingham injected a foam sealant into the lungs of a former smoker on Oct. 29, 2012, to treat his worsening emphysema. He was the first patient in the United States treated in a late-stage clinical trial of the AeriSeal System.

3 Nov 2012

Researcher identifies 71 genetic regions newly associated with inflammatory bowel disease

In one of the largest studies of its kind ever conducted, an international team of scientists has thrown new light on the genetic basis of the inflammatory bowel diseases (IBD).

3 Nov 2012

MH6 vaccine shows promise in treating meth addiction

Scientists at The Scripps Research Institute (TSRI) have performed successful tests of an experimental methamphetamine vaccine on rats. Vaccinated animals that received the drug were largely protected from typical signs of meth intoxication.

2 Nov 2012

Study explores impact of IL1β on brain function alterations associated with schizophrenia

There are a growing number of clues that immune and inflammatory mechanisms are important for the biology of schizophrenia. In a new study in Biological Psychiatry, Dr. Mar Fatjó-Vilas and colleagues explored the impact of the interleukin-1β gene (IL1β) on brain function alterations associated with schizophrenia.

2 Nov 2012

Multiple sclerosis disease activity reduced by leukaemia drug, even when first-line treatment has failed

A drug which was originally developed to treat leukaemia and other cancers of the immune system offers substantial improvements over existing treatments in reducing relapse rates for people with multiple sclerosis (MS), even when they have not responded well to first-line treatment, according to the results of two phase 3 trials published Online First in The Lancet.

1 Nov 2012

Study finds link between severe sepsis and chronic diseases

It's a major cause of death, yet few of us have ever heard of it. Sepsis occurs when a patient's immune system overreacts to an infection, triggering a potentially fatal, system-wide inflammation. Severe sepsis strikes about 750,000 Americans each year, most of them older and often ill, with as many as half of these patients dying as septic shock shuts down their organs. Furthermore, patients in many Southern states are about twice as likely to develop sepsis for reasons unknown.

1 Nov 2012

Clinical hypnosis can effectively reduce hot flashes among postmenopausal women

Clinical hypnosis can effectively reduce hot flashes and associated symptoms among postmenopausal women, according to a new study conducted by researchers at Baylor University's Mind-Body Medicine Research Laboratory.

1 Nov 2012

Regular blood test may help predict survival in patients with Merkel cell carcinoma

A routine blood test may help predict survival in patients with an aggressive form of skin cancer known as Merkel cell carcinoma, according to new findings by Fox Chase Cancer Center researchers. The results will be presented on Wednesday, October 31 at the American Society for Radiation Oncology's 54th Annual Meeting.

1 Nov 2012

Exosomes alone could protect infants' lungs from dangerous inflammation

Researchers at Boston Children's Hospital have found that microscopic particles containing proteins and nucleic acids called exosomes could potentially protect the fragile lungs of premature babies from serious lung diseases and chronic lung injury caused by inflammation.

1 Nov 2012

Microbiologists confirm existence of new tick disease in Switzerland

Until now, we knew that ticks primarily transmit two pathogens to humans in Switzerland: the bacterium Borrelia burgdorferi - which causes borreliosis - and the early-summer-meningoencephalitis virus, which can cause cerebral inflammation. Now, microbiologists from the University of Zurich confirm the existence of another tick disease in Switzerland - neoehrlichiosis.

1 Nov 2012

Single dose of etanercept can improve chronic neurological dysfunction from stroke or TBI

A new ground-breaking study about to be published in the Adis journal CNS Drugs provides clinical evidence that, for the first time, chronic neurological dysfunction from stroke or traumatic brain injury can rapidly improve following a single dose of a drug that targets brain inflammation, even years after the stroke or traumatic event.

1 Nov 2012

Physically active men produce better semen quality

A new study conducted by researchers at the University of Cordoba links moderate physical activity in males with better hormone levels and sperm characteristics that favour reproduction compared to sedentary men.

1 Nov 2012

Scientists discover first selective inhibitors of DAGL enzymes

Scientists at The Scripps Research Institute (TSRI) have discovered the first selective inhibitors of an important set of enzymes. The new inhibitors, and chemical probes based on them, now can be used to study the functions of enzymes known as diacylglycerol lipases (DAGL), their products, and the pathways they regulate.

1 Nov 2012

Immune System News and Research

SCYNEXIS announces results from SCY-635 Phase 2a study on HCV

Researchers show how bacteria control processes in human cells

Pfizer receives FDA approval for Xeljanz to treat rheumatoid arthritis

Sabin initiates Part II of Na-GST-1 vaccine Phase I hookworm trial

Bristol-Myers Squibb welcomes decision by NICE to recommend Yervoy for advanced melanoma

NICE decides to recommend Bristol-Myers Squibb’s YERVOY for treatment of advanced melanoma

Baylor University receives two new federal grants for research on Gulf War illness

AeriSeal System appears to be effective in treating emphysema

Researcher identifies 71 genetic regions newly associated with inflammatory bowel disease

MH6 vaccine shows promise in treating meth addiction

Study explores impact of IL1β on brain function alterations associated with schizophrenia

Multiple sclerosis disease activity reduced by leukaemia drug, even when first-line treatment has failed

Study finds link between severe sepsis and chronic diseases

Clinical hypnosis can effectively reduce hot flashes among postmenopausal women

Regular blood test may help predict survival in patients with Merkel cell carcinoma

Exosomes alone could protect infants' lungs from dangerous inflammation

Microbiologists confirm existence of new tick disease in Switzerland

Single dose of etanercept can improve chronic neurological dysfunction from stroke or TBI

Physically active men produce better semen quality

Scientists discover first selective inhibitors of DAGL enzymes

Understanding the DNA Damage Response in Innate Immunity eBook

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer

Latest News